BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

26 related articles for article (PubMed ID: 27668530)

  • 1. Management of metastatic bone disease of melanoma.
    Chen W; Yang C; Chen B; Xi M; Chen B; Li Q
    Melanoma Res; 2024 Feb; 34(1):22-30. PubMed ID: 37939058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BONE MARKERS IN ARTHROPATHIES.
    Răduț R; Crăciun AM; Silaghi CN
    Acta Clin Croat; 2019 Dec; 58(4):716-725. PubMed ID: 32595257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The possibility of the serum concentration of osteocalcin determination in lung cancer patients with suspected bone metastases].
    Weissensteiner J; Babušíková E
    Klin Onkol; 2015; 28(1):51-6. PubMed ID: 25692755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The value of human epididymis protein 4 (HE4) as a serum tumor marker for accurate bone metastases finding by whole-body bone scintigraphy in lung cancer patients.
    Weissensteiner J; Babusikova E
    Neoplasma; 2019 Nov; 66(6):1024-1030. PubMed ID: 31307200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
    Pollmann D; Siepmann S; Geppert R; Wernecke KD; Possinger K; Lüftner D
    Anticancer Res; 2007; 27(4A):1853-62. PubMed ID: 17649784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical studies using measurement of N-telopeptides of type 1 collagen (NTx) in patients with bone metastasis--comparison with bone scintigraphy and other metabolic bone markers].
    Yamamoto I; Morita R; Konishi J; Shigeno C; Ikekubo K; Hino M; Sone T; Fujimoto R
    Kaku Igaku; 1995 May; 32(5):501-10. PubMed ID: 7596071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients.
    Ebert W; Muley T; Herb KP; Schmidt-Gayk H
    Anticancer Res; 2004; 24(5B):3193-201. PubMed ID: 15510610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone Metabolism of the Patient with a Malignant Melanoma during the Entry Examination and the Check-up of Whole-body Bone Scintigraphy.
    Weissensteiner J; Babušíková E
    Prague Med Rep; 2016; 117(2-3):129-134. PubMed ID: 27668530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Bone scintigraphy for diagnosis of bone metastasis in patients with prostatic cancer].
    Nakashima J
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():135-9. PubMed ID: 12599559
    [No Abstract]   [Full Text] [Related]  

  • 10. [Evaluation of cancer-induced bone diseases by bone metabolic marker].
    Takahashi S
    Clin Calcium; 2006 Apr; 16(4):581- 90. PubMed ID: 16582508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum markers of cutaneous melanoma.
    Perrotta R; Bevelacqua Y; Malaguarnera G; Paladina I; Giordano M; Malaguarnera M
    Front Biosci (Elite Ed); 2010 Jun; 2(3):1115-22. PubMed ID: 20515782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Malignant melanoma--markers for progression and prognosis in malignant melanoma.
    Geilen CC; Georgieva J; Milling A; Farthmann B
    Front Radiat Ther Oncol; 2006; 39():120-126. PubMed ID: 16394675
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.